Long term outcomes of radical radiotherapy with hypoxia modification with biomarker discovery for stratification: Ten year update of the BCON (Bladder CarbOgen Nicotinamide) phase III randomised trial (ISRCTN45938399)
AuthorsSong, Yee Pei
Irlam, Joely J
Valentine, Helen R
West, Catharine M L
Hoskin, Peter J
AffiliationDivision of Cancer Sciences, The University of Manchester, Manchester, UK; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, U
MetadataShow full item record
AbstractBackground: Many muscle invasive bladder cancers are hypoxic which limits efficacy of radiotherapy. Hypoxia modification using carbogen and nicotinamide has been tested in a phase III trial, XXXX. We present mature follow up with biomarker prediction of outcome. Patients and methods: XXXX is a prospective phase III multicentre randomised two arm non-blind clinical trial. Randomisation was to a control arm receiving radical radiotherapy alone or with the addition of carbogen (98% O2, 2% CO2) and nicotinamide (CON). Patients with muscle invasive or high grade non muscle invasive bladder cancer were included. Tumour tissue was collected at entry and has been analysed for tumour necrosis, hypoxia (24-gene signature) and basal and luminal tumour molecular subtypes. Overall and disease free survival and relationships with biomarker status outcome are analysed using multivariable Cox regression and log-rank analysis. Results: 333 patients with a median follow up of 10.3 years were analysed. 10-year OS rates were 30% (95% CI 0.23-0.39) in RT+CON patients and 24% (95% CI 0.18-0.33) in the RT alone patients (HR = 0.80; 95% CI: 0.61-1.04; p=0.08). Greatest benefit from CON is seen in patients with tumour necrosis (n=79; 5 yr OS 53% v 33%; HR 0.59; 95% CI 0.36-0.99; p=0.04). The results for high hypoxia gene score (n=75) were 5 yr OS 51% v 34%; HR 0.64; 95% CI 0.38-1.08; p=0.09 and molecular subtype basal (n=70) were 5 yr OS 58% vs 38%; HR 0.58; 95% CI 0.32-1.06; p=0.08. Conclusions: Although the improvement in long term overall survival in the whole population is not statistically significant, patients selected by necrosis and a high hypoxia gene score benefitted from hypoxia modification.
CitationSong YP, Mistry H, Irlam J, Valentine H, Yang L, Lane B, et al. Long term outcomes of radical radiotherapy with hypoxia modification with biomarker discovery for stratification: Ten year update of the BCON (Bladder CarbOgen Nicotinamide) phase III randomised trial (ISRCTN45938399). Int J Radiat Oncol Biol Phys. 2021.
JournalInternational Journal of Radiation Oncology Biology Physics
- Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
- Authors: Eustace A, Irlam JJ, Taylor J, Denley H, Agrawal S, Choudhury A, Ryder D, Ord JJ, Harris AL, Rojas AM, Hoskin PJ, West CM
- Issue date: 2013 Jul
- A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients.
- Authors: Yang L, Taylor J, Eustace A, Irlam JJ, Denley H, Hoskin PJ, Alsner J, Buffa FM, Harris AL, Choudhury A, West CML
- Issue date: 2017 Aug 15
- A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
- Authors: Eustace A, Mani N, Span PN, Irlam JJ, Taylor J, Betts GN, Denley H, Miller CJ, Homer JJ, Rojas AM, Hoskin PJ, Buffa FM, Harris AL, Kaanders JH, West CM
- Issue date: 2013 Sep 1
- Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer.
- Authors: Irlam-Jones JJ, Eustace A, Denley H, Choudhury A, Harris AL, Hoskin PJ, West CM
- Issue date: 2016 Aug 23
- Expression of hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancer.
- Authors: Hunter BA, Eustace A, Irlam JJ, Valentine HR, Denley H, Oguejiofor KK, Swindell R, Hoskin PJ, Choudhury A, West CM
- Issue date: 2014 Jul 29